Today, Aug. 19, 2026, Moderna’s personalized cancer vaccine met its late-stage goal, with the company and Merck planning an FDA submission.
Stock Market Today, Aug. 19: Moderna Skyrockets 177% on Positive Phase 3 Melanoma Data
view original post
Today, Aug. 19, 2026, Moderna’s personalized cancer vaccine met its late-stage goal, with the company and Merck planning an FDA submission.